Of the simulated cohorts, biosimilar substitution led to a reduction in TCOC in 9996 of 10,000 relative to benchmark. In the 10,000 simulations of use of reference products only, ...

Formycon currently anticipates that FYB206 could enter the U.S. market after Keytruda’s exclusivity expires in 2029, and in ...

Automatic Substitution With Interchangeable Biosimilars. EP: 5.Biosimilar and Interchangeable Biosimilar Conversion Programs. EP: 6.2023 Biosimilars Landscape.

LAS VEGAS -- Use of biosimilars for cancer care increased at a network of community oncology practices following the implementation of a pharmacist-led biosimilar substitution program, and cost ...

The biosimilar substitution rule would apply to all enrollees, including those taking the reference product prior to the effective date of change. The update is consistent with requests from ASHP ...

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, ... different rules apply for notifying the prescribing doctor about a biosimilar substitution.

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Biosimilars' Excellent Track Record ... "Medication substitution can occur when insurers or pharmacy benefit managers change formulary coverage, typically for financial reasons," Leeolou said.

The launch of eight adalimumab biosimilars so far this year ended Humira's 20-year monopoly, ... Forty-seven states allow for these substitutions without prior approval from a clinician, ...

The Food and Drug Administration (FDA) has approved Selarsdi ™ (ustekinumab-aken) as interchangeable to the reference product Stelara ® (ustekinumab).. Selarsdi, a human interleukin-12 and -23 ...